DICE Therapeutics, Inc. Common Stock
DICE
DICE was delisted on the 8th of August, 2023.
79 hedge funds and large institutions have $748M invested in DICE Therapeutics, Inc. Common Stock in 2022 Q3 according to their latest regulatory filings, with 12 funds opening new positions, 31 increasing their positions, 16 reducing their positions, and 12 closing their positions.
163% more call options, than puts
Call options by funds: $55.9M | Put options by funds: $21.3M
94% more repeat investments, than reductions
Existing positions increased: 31 | Existing positions reduced: 16
33% more capital invested
Capital invested by funds: $565M → $748M (+$184M)
0% more funds holding in top 10
Funds holding in top 10: 4 → 4 (0)
0% more first-time investments, than exits
New positions opened: 12 | Existing positions closed: 12
1% less funds holding
Funds holding: 80 → 79 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
+$27.6M |
| 2 |
VA
VR Adviser
New York
|
+$13.9M |
| 3 |
BlackRock
New York
|
+$3.43M |
| 4 |
Balyasny Asset Management
Chicago,
Illinois
|
+$3.37M |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
+$3.11M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
EAM
Eventide Asset Management
Boston,
Massachusetts
|
-$20.8M |
| 2 |
PA
Perceptive Advisors
New York
|
-$6.64M |
| 3 |
Citadel Advisors
Miami,
Florida
|
-$5.81M |
| 4 |
SCM
Soleus Capital Management
Greenwich,
Connecticut
|
-$5.11M |
| 5 |
DCM
Driehaus Capital Management
Chicago,
Illinois
|
-$4.71M |
DICE Hedge Fund Activity: Q3 2022 in Review
79 of the 5,828 institutional investors tracked by Wall St. Rank reported a position in DICE Therapeutics, Inc. Common Stock (DICE) for Q3 2022, worth a combined $748M — up 33% from $565M a quarter earlier.
Fund positioning in DICE was balanced in Q3 2022: 12 funds opened new positions, 12 closed out, 31 added to existing stakes and 16 trimmed.
The largest buyer was Fidelity Investments, adding an estimated $27.6M. The largest seller was Eventide Asset Management, exiting entirely with an estimated $20.8M sold.
- 79 institutional investors held DICE Therapeutics, Inc. Common Stock (DICE) as of Q3 2022, down from 80 in Q2 2022.
- Funds reported $748M of DICE Therapeutics, Inc. Common Stock stock for Q3 2022, up 33% quarter-over-quarter.
- 12 funds opened new DICE Therapeutics, Inc. Common Stock positions in Q3 2022 and 12 closed out, a net change of 0 holders.
- The largest DICE Therapeutics, Inc. Common Stock buyer in Q3 2022 was Fidelity Investments, an estimated $27.6M added.
- The largest DICE Therapeutics, Inc. Common Stock seller in Q3 2022 was Eventide Asset Management, an estimated $20.8M sold.
Based on aggregated 13F filings for Q3 2022.